Incyte Corporation

INCY 
(NASDAQ) 
 
$ 73.96 <%= Resources.Global.txtDown %>
Updated 17/04/2019
Change % -0.48% Stock price decreasing
Change -0.36 Stock price decreasing
Volume 1,171,586
High $ 75.71
Low $ 72.43
Open $ 74.74
ISIN
Prev close $ 74.32
# of shares 214.26M
Market cap 15,847M USD
Intraday

Market closed
Incyte Corporation
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  73.96 -6.9% Stock price decreasing -15.1% Stock price decreasing -5.7% Stock price decreasing 12.0% Stock price increasing 8.1% Stock price increasing
Powered by TradingView

News about Incyte Corporation

  • English
  • Regulatory news

Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 10:00:45
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB5 - 2019-04-21 11:00:45 - 2019-04-21 10:00:45 - 1000 - Website: OKAY